← Back to Search

Monoclonal Antibodies

Lucentis plus Reduced Fluence PDT same day for Age-Related Macular Degeneration

N/A
Waitlist Available
Led By Gaurav K. Shah, MD
Research Sponsored by Barnes Retina Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with visual acuity of 20/40-20/320 in the study eye
Blood associated with the lesion at baseline
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months and 24 months
Awards & highlights

Study Summary

The purpose of this study is to determine the benefits, if any, of combination therapy with Lucentis plus reduced fluence photodynamic therapy with Visudyne.

Eligible Conditions
  • Age-Related Macular Degeneration

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months and 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess efficacy of the two timing regimens
To assess the safety of the combination therapy
Secondary outcome measures
To evaluate the number of Lucentis injections and the number of PDT treatments required during the study

Trial Design

2Treatment groups
Active Control
Group I: Lucentis plus Reduced Fluence PDT same dayActive Control2 Interventions
Group II: Lucentis plus reduced fluence PDT 1-2 weeks laterActive Control2 Interventions

Find a Location

Who is running the clinical trial?

Barnes Retina InstituteLead Sponsor
10 Previous Clinical Trials
791 Total Patients Enrolled
QLT Inc.Industry Sponsor
28 Previous Clinical Trials
3,112 Total Patients Enrolled
Gaurav K. Shah, MDPrincipal InvestigatorBarnes Retina Institute
1 Previous Clinical Trials
22 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025